Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel

Cispaltin based chemotherapies are standard for palliative first-line therapy in patients with advanced or metastatic NSCLC. Due to contraindications to cisplatin, this substance can not be used in a high number of patients. Especially in elderly patients, patients with comorbidities and patients with reduced general condition, cisplatin is a therapy which often induces intolerable toxicities. Thus, therapy often has to be interrupted or finished prematurely. Due to its favorable toxicity profile, oxaliplatin can be used also for the treatment of elderly patients and patients with comorbidities. Based on toxicity data from a phase II study of our group in patients with gastric cancer, the dosage for oxaliplatin/docetaxel was adopted for this actual study. In previous phase II trials, response rates of oxaliplatin based combination chemotherapies were comparable to those with cisplatin in patients with metastatic NSCLC.

In this study we will analyse, if a oxaliplatin based combination chemotherapy has a more tolerable toxicity profile and comparable or even better response rate in comparison to a cisplatin based chemotherapy. 44 patients in each arm will either be treated with a maximum of 6 cycles cisplatin/docetaxel or a maximum of 8 cycles oxaliplatin/docetaxel.

Inclusion criteria

• histologically or cytologically confirmed NSCLC stage IIIB or IV.
• no previous chemotherapy in metastatic state
• male and female patients aged > 18 years
• ECOG ≤ 2
• Leukocytes > 3.000/µl
• Thrombocytes > 100.000/µl
• Serum creatinine ≤ 1.25x normal value, or Creatinine Clearance > 45 ml/min
• previous radiation < 25% bone marrow region allowed. Previous radiation of whole pelvis not allowed
• parallel radiation allowed, if target lesion outside of radiation field
• written informed consent
• life expectancy > 3 months

Exclusion criteria

• hypersensibility against Cisplatin, Oxaliplatin or Docetaxel
• Neoadjuvant or adjuvant chemotherapy within the last 6 months
• radiation within the last 28 days
• severe systemic comorbidities
• Cardiomyopathy or cardiac insufficiency stage II-IV according to NYHA
• malignant secondary disease, dated back < 5 years (exception: In-situ-carcinoma of the cervix uteri, adequately treated skin basal cell carcinoma)
• brain metastases
• severe non-surgical comorbidities or acute infection
• peripheral polyneuropathy > NCI grade II
• severe liver dysfunction AST/ALT>3,5xULN, AP>6xULN, Bilirubin>1,5xULN)
• participation in parallel trial
• pregnancy and lactation
• reduced hearing